Abstract: A treatment method for a variety of neurological conditions using a novel combination of near infrared (NIR) light therapy and the pharmacological agent ketamine. After administration of ketamine to a patient, NIR is aimed through the scalp at the brain, preferably targeted at the brain regions most affected. In addition, certain dietary supplements and an exercise program may be offered. Combined, these therapies have proved much more effective than the sum of their individual efficacies.

Abstract: A treatment method for a variety of neurological conditions using a novel combination of near infrared (NIR) light therapy and the pharmacological agent ketamine. After administration of ketamine to a patient, NIR is aimed through the scalp at the brain, preferably targeted at the brain regions most affected. In addition, certain dietary supplements and an exercise program may be offered. Combined, these therapies have proved much more effective than the sum of their individual efficacies.

Abstract: A treatment method using a novel combination of non-invasive near infrared light (NIR)/laser therapy and the pharmacological agent ketamine, to more efficaciously upregulate neurotrophins and improve mitochondrial function. The NIR therapy is characterized by wavelengths of 200-2000 nm at surface wattage of 0.01-50.00 watts delivered by stationary emitters. The method can employ active circular motion techniques which involve moving the infrared light applicator manually, and/or by computer-controlled apparatus, conducted in conjunction with ketamine pharmacological therapy. In addition, a novel method of targeting NIR treatment of and characterizing central nervous system disorders using SPECT functional neuroimaging followed by quantitative analysis and a novel method of targeting NIR treatment of and characterizing spinal cord or nerve-related disorders using neurophysiological testing followed by quantitative analysis.

Abstract: A treatment method using a novel combination of non-invasive near infrared light (NIR)/laser therapy and the pharmacological agent ketamine, to more efficaciously upregulate neurotrophins and improve mitochondrial function. The NIR therapy is characterized by wavelengths of 200-2000 nm at surface wattage of 0.01-50.00 watts delivered by stationary emitters. The method can employ active circular motion techniques which involve moving the infrared light applicator manually, and/or by computer-controlled apparatus, conducted in conjunction with ketamine pharmacological therapy. In addition, a novel method of targeting NIR treatment of and characterizing central nervous system disorders using SPECT functional neuroimaging followed by quantitative analysis and a novel method of targeting NIR treatment of and characterizing spinal cord or nerve-related disorders using neurophysiological testing followed by quantitative analysis.

Abstract: An exemplary method of treatment involves the non-invasive delivery of near infrared light (NIR) in 600-1200 nm wavelengths at surface wattage of 10.01-20.00 watts applied using a continuous motion technique. Treatment duration can be 30-1800 seconds, and can be conducted using a specific pulsed NIR technique for minimizing surface tissue heating. This is a novel process of non-invasive NIR/laser therapy. Prior applications used low levels of NIR therapy—most less than 1 watt with some up to 5 watts. Embodiments of the methodologies can be practiced with a laser unit having control for wavelength and for 1-20 watts. A Pulsed (on/off laser beam) control for 1-1000 milliseconds may also be utilized. An applicator with 1-2 cm aperture can be used to produce approximately 0.64-1.95 Joules per cm2 fluence in the depth of tissue. A display detailing watts, time, continuous or pulsing, and Joules of therapy is useful.